PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,226,709 | covid deal ventil shortag describ differ strategi adopt coronavirus diseas pandem cope shortag mechan ventil | D000086382 | T047;T067 |
36,226,707 | impact icu strain outcom acut surg event result health capac strain result deviat normal care activ conting decis relat resourc alloc review discuss impact health capac strain patient center outcom | D016638;D000086382 | T047;T067 |
36,226,706 | transfus manag trauma patient transfus blood product lifesav trauma icu intensivist must familiar contemporari literatur develop optim transfus strategi patient | D012771;D001778;D014947 | T047;T046;T037 |
36,226,701 | shorten lifespan induc high glucos diet associ intestin immun dysfunct drosophila sechellia organ general divid two nutrit group generalist consum various type food specialist consum specif type food howev remain unclear specialist adapt limit nutrit condit natur studi address question focus drosophila fruit fli generalist drosophila melanogast consum wide varieti food contain high glucos level contrast specialist drosophila sechellia consum indian mulberri known noni morinda citrifolia contain relat littl glucos show lifespan sechellia signific shorten high glucos diet effect observ melanogast sechellia high glucos diet induc disorgan gut epithelia viscer muscl associ abnorm digest constip rna sequenc analysi reveal mani immun respons gene suppress gut sechellia fed high glucos diet compar fed control diet consist differ express immun respons gene high glucos induc phenotyp restor addit tetracyclin scopoletin major nutrit compon noni suppress gut bacteri growth propos sechellia high glucos diet impair gut immun function lead chang gut microbiota disorgan gut epitheli structur shorten lifespan | D004330;D032066 | T002;T204 |
36,226,683 | remov bap soil biochar prepar medicago corn straw use batch solid phase extract method low cost materi high effici adsorpt capabl prepar corn straw medicago abbrevi cb mb effect remov benzo pyren bap contamin soil prepar temperatur c limit oxygen condit appear trait content c h n function group type cb mb obtain sem element analysi ft ir batch method found adsorpt bap cb mb accord pseudo secondari kinet correl coeffici cb mb respect maximum adsorpt capac fit cb mg kg mb mg kg consist actual measur cb mg kg mb mg kg freundlich langmuir equat well describ isotherm adsorpt data cb mb due correl coeffici greater soil sampl treat ase separ solid phase extract spe differ biochar content pack column found contribut cb mb remov bap increas respect could effect reduc bap pollut soil | D012987;D003313 | T167;T168;T002 |
36,226,681 | depth theoret understand chemic interact aromat compound gold nanoparticl gold nanoparticl gnps owe uniqu properti versatil prepar strategi demonstr exhibit promis applic divers field includ bio sensor catalyst nanomedicin radiotherapi yet natur interfaci interact gnps chemic environ remain elus experiment vibrat spectroscopi reveal differ interact aromat biolog molecul absorb gnps may result chang orient molecul howev presenc multipl function group aqueous solvent introduc competit complexifi spectral interpret therefor object theoret investig adsorpt aromat molecul contain various function group surfac gnps compar studi prefer adsorpt mode interact au model gnps seri substitut aromat compound includ benzen anilin phenol toluen benzoic acid acetophenon methyl benzoat thiophenol investig comput interact energi highlight prefer aromat ring lie flat surfac orient molecul distinguish use infrar spectroscopi along strong chang intens signific shift vibrat mode molecul interact gnp interact energi electron transfer nanoparticl aromat molecul found correl possibl signific back donat electron gnps organ molecul reveal charg decomposit analysi thorough quantum topolog analysi identifi multipl non coval interact assign natur interact most dativ interact aromat ring gnp well dispers interact final energi decomposit analys point role charg transfer energi contribut subtl balanc differ physic compon | D006046;D053768 | T121;T196;T073 |
36,226,675 | lysophosphatid acid acyltransferas lpat requir de novo glycerolipid biosynthesi growth develop veget reproduct tissu arabidopsi kennedi pathway high conserv de novo glycerolipid biosynthesi pathway prokaryot eukaryot arabidopsi lysophosphatid acid acyltransferas lpat assum catalyz crucial reaction step endoplasm reticulum er local kennedi pathway lethal lpat knockout mutant howev whether lethal phenotyp due essenti role kennedi pathway lpat key enzym kennedi pathway unclear creat non lethal lpat knockdown mutant arabidopsi found lpat requir phospholipid content plant develop veget reproduct growth function vivo report assay reveal lpat ubiquit express local er de novo phospholipid biosynthesi take place intrigu lipid analysi reveal lpat suppress differ effect among organ examin phospholipid level decreas leav flower effect pronounc flower non photosynthet organ enrich phospholipid although seed size reduc lpat suppress line remark effect observ lipid content matur siliqu result show lpat involv er local kennedi pathway suggest contribut de novo phospholipid biosynthesi may organ select | D017360;D029681 | T116;T002 |
36,226,668 | genet delet hspa lead select tissu malform zebrafish embryon develop heat shock cognat kda protein hspa also known hsc constitut express cognat member heat shock protein famili play essenti role protein qualiti control cell homeostasi mainten hspa implic mani diseas includ cancer neurodegen diseas owe massiv cell death knockdown hspa nonviabl hspa knockout mice physiolog role hspa vertebr under mechan action yet elucid address issu use crisprca technolog genet delet hspa zebrafish embryo genet delet hspa result malform pharyng arch pector fin head eye later stage next focus pharyng arch defici found pharyng arch hspa mutant embryo exhibit induct endoplasm reticulum stress activ unfold protein respons via perkp eifatf signal cascad inhibit perkp eifatf signal rescu development defici pharyng arch caus deplet hspa taken togeth result provid novel insight tissu specif role hspa regul vertebr embryon develop | D015027;D015852 | T123;T116;T013 |
36,226,664 | neuromuscular organ haptor armament polyclithrum ponticum monogenea gyrodactylida gyrodactylid haptor arm pair hamuli two connect bar margin hook gyrodactylid howev haptor disc shape reinforc addit sclerit genus polyclithrum arguabl elabor haptor group studi aim gain better understand anatomi polyclithrum examin neuromusculatur haptor armament polyclithrum ponticum speci parasit mugil cephalus black sea emphasi haptor sclerit musculatur connect host attach mechan musculatur stain phalloidin nervous system anti serotonin anti fmrfamid antibodi haptor sclerit visual reflect light studi provid new inform sclerit addit previous describ supplementari sclerit ear shape sclerit esss two pair group rib reflect light reveal rod shape process esss pair small posterior sclerit sclerit shown oper muscl promin two transvers muscl connect hamular root three muscl attach sclerit muscl fibr anterior rib set extrins muscl nervous system consist pair cerebr ganglia connect commissur three pair nerv cord unit haptor form loop opposit cord arrang sclerit muscl suggest polyclithrum initi attach clamp host surfac longitudin fold haptor secur posit margin hook | D014200 | T204 |
36,226,658 | individu coat entomopathogen nematod titania tio nanoparticl base oil water picker emuls new formul biopesticid studi present new eco friend formul entomopathogen nematod epn base individu coat epn titanium dioxid tio nanoparticl nps miner oil via oil water picker emuls miner oil water emuls stabil amin function titanium dioxid tio nh particl prepar oil water volum ratio use wt tio nh particl found stabl emuls droplet size suitabl formul studi toxic incorpor epn carboxyfluorescein coval bond tio nh nps result composit observ via fluoresc confoc microscopi dri coat evalu use sem confoc microscopi show signific nematod coverag particl oil final formul biocompat studi epn viabil epn formul equival control aqueous suspens day final yield nematod infect galleria mellonella cadav collect day show signific differ p use test emuls compar control contain nematod water | D053758;D009348 | T073;T204 |
36,226,652 | tscl promot thiolat quinolin n oxid thiophenol metal free method regioselect synthesi thiolat quinolin quinolin n oxid water room temperatur develop reaction conduct use benzenethiol thiolat reagent presenc p toluenesulfonyl chlorid via p toluenesulfonyl chlorid assist tandem c h bond activ nucleophil addit deoxygen aromat process method requir use metal catalyst oxid show advantag wide function group toler short reaction time simpl oper | D010087;D011804 | T109;T197 |
36,226,637 | insect perspect z disc structur biolog myofibril intracellular structur form actin myosin filament paracrystallin contractil cabl unusu well defin dimens slide actin past myosin filament power contract entir system held place structur call z disc anchor actin filament myosin filament turn anchor anoth structur call line complex architectur myofibril reduc studi z disc recent import advanc regard arrang function z disc insect publish small scale detail protein structur inform medium scale cryo electron microscopi map super resolut microscopi protein protein interact network function scale phenotyp data avail precis genet manipul data aim answer z disc work assembl summar recent data insect explor fit view z disc myofibril ultim muscl | D000199;D012518 | T026;T123;T116 |
36,226,636 | biomass deriv self assembl dna dot hydrogel enhanc bacteri annihil nanot biomass interest biomed applic still nascent stage visibl market avail product product deriv biomass dna protein unquestion biocompat induct desir properti need care manipul biomolecul herein first time report transform onion deriv biomass dna dna dot partial hydrotherm pyrolysi induc improv mechan photophys properti dna dot use crosslink creat hydrogel hybrid mediat self assembl untransform genom dna dna dot dna hydrogel sustain deliv ciprofloxacin antibiot well produc demand reactiv oxygen speci ros visibl light irradi prompt us explor hydrogel topic formul combin antibiot antibacteri photodynam therapi apdt applic remark annihil e coli aureus import two drug resist strain e coli show success sustain approach | D013211;D020100 | T007;T122 |
36,226,633 | arginyl fructosyl glucos major maillard reaction product red ginseng mitig cisplatin evok intestin toxic vivo vitro cisplatin evok profound gastrointestin symptomatolog one common side effect chemotherapi drug caus gastrointestin cell damag diarrhea vomit panax ginseng c meyer wide use medicin edibl plant china show mani pharmacolog activ nevertheless role non saponin less known great potenti treatment sever toxic side effect relat cisplatin treatment present work evalu effici major maillard reaction product mrp red ginseng arginyl fructosyl glucos afg cisplatin evok intestin toxic vivo vitro under possibl mechan also explor cisplatin treat mice dose mg kg one time show serious intestin mucosa damag accompani increas indic diamin oxidas dao decreas express tight junction protein zonula occluden zo occludin moreov cisplatin exposur increas intestin cell apoptosi decreas express bcl increas express bax cleav caspas well nf b relat protein interest supplement afg dose mg kg day day signific amelior chang also demonstr cultur iec cell afg enhanc express level apoptot protein cisplatin exposur reduc sensit iec cell cisplatin inhibit activ gsk regul protein express catenin conclus afg exert protect effect cisplatin induc intestin toxic least partial inhibit nf b mediat apoptosi via regul wnt catenin signal pathway | D002945;D005894 | T121;T002;T197 |
36,226,632 | direct c sp h polyfluoroaryl access polyfluoroaryl amino acid via rh catalyz select c f bond cleavag catalyt select c f bond alkyl method polyfluoroaren glycin deriv presenc davepho ligat rh catalyst develop method avoid preactiv alkyl reagent provid effici straightforward rout synthes seri polyfluoroaryl amino acid via c sp h function reaction proceed mild condit exhibit high reactiv excel chemoselect meanwhil synthet potenti method demonstr gram scale synthesi transform prove applic valu product well | D012238 | T196 |
36,226,623 | dual target fluoresc probe simultan discrimin visual lipid droplet endoplasm reticulum singl fluoresc probe sf probe simultan discrimin visual two organell power tool investig interact cellular process howev still challeng develop uniqu type fluoresc probe due lack feasibl design strategi herein propos dual target group strategi construct sf probe integr two differ organell target group fluorophor versatil fluorophor two nonintrus organell target group element strategi view sf probe develop simultan discrimin imag lipid droplet lds endoplasm reticulum er proof concept sf probe lder design synthes introduc ld target group er target group onto naphthalimid fluorophor owe specif structur fluorophor target group two termin naphthalimid fulli play respect role without mutual interfer furthermor abil two group target respect target compar enabl lder bind lds er even meanwhil lder suscept polar advantag discrimin imag lds er addit interact lds er investig | D066292;D005456 | T026;T130 |
36,226,621 | distinct effect differ type advanc glycat end product age liver glucos metabol increas evid shown age impair insulin sensit affect glucos homeostasi owe heterogen age still unclear one strongest potenti disrupt glucos metabol studi explor effect differ type age hepat glucos metabol three typic age repres differ format pathway name age glucos lysin reaction mixtur methylglyox modifi bsa mgo bsa carboxymethyl lysin cml chosen treat hepg cell result indic cml mgo bsa could disturb glucos metabol mgo bsa activ promot insulin resist manifest inactiv insulin receptor substrat decreas phosphoryl akt moreov mice fed mgo bsa enrich diet show increas blood glucos well impair glucos toler present studi reveal distinct effect various age glucos metabol suggest age high molecular weight might exert higher pathogen effect small age | D005947;D007333 | T121;T109;T123;T046 |
36,226,583 | intramolecular c n bond activ geometr constrain p iii centr work first exampl c n bond activ insert geometr constrain p iii centr shown mechan activ process lead new p v speci studi experiment comput interest case insert p iii centr n c h bond unstabl phosphoranyl formaldehyd intermedi probabl form undergo decarbonyl presenc catalyt amount hcl produc hydrophosphoran | D002384 | T070 |
36,226,573 | integr chromatograph approach discoveri gingerol antioxid dracocephalum heterophyllum potenti target tradit tibetan medicin dracocephalum heterophyllum mani benefit due complic procedur separ purif chemic constitu report gingerol studi four antioxid gingerol isol dracocephalum heterophyllum integr chromatograph approach antioxid activ determin vitro experi potenti target action investig first extract pretreat use silica gel mci gelchpp diol spheric medium pressur column antioxid peak identifi use onlin hplc diphenyl picrylhydrazyl system antioxid peak direct separ purifi high pressur liquid chromatographi obtain four gingerol puriti higher name methoxi gingerol shogaol paradol diacetoxi gingerdiol final diphenyl picrylhydrazyl assay cellular antioxid experi carri molecular dock use explor potenti antioxid target isol gingerol upregul activ antioxid enzym includ superoxid dismutas sod heme oxygenas ho nadph oxidas nox littl effect activ nadph quinon oxidoreductas nqo method effici prepar isol antioxid gingerol dracocephalum heterophyllum extend isol antioxid natur product | D000975;D010936 | T121;T044;T123;T039 |
36,226,571 | origin time de novo variant implic type von willebrand diseas studi shown real origin time de novo variant dnv implic von willebrand diseas vwd investig four famili type vwd first conduct linkag analysi use singl nucleotid variant genotyp recogn possibl proven dnv second perform amplif refractori mutat system quantit polymeras chain reaction confirm real origin variant mutant cell presenc genet mosaic variant mutant cell three embryon germ layer deriv tissu sperm cell three possibl time dnv categor base relat likelihood occurr accord number cell divis embryogenesi two type b vwd proband pargci proband pargtrp type vwd proband pleuarg proband pserleu identifi variant origin identifi famili confirm origin mother father father respect howev father famili confirm isol germlin mosaic mutant sperm cell investig confirm patern grandfath origin variant thus propos dnv origin two father like occur singl sperm cell one origin mother occur zygot first cellular divis altern famili dnv like occur earli postzygot develop father find essenti understand genet pathogenesi provid accur genet counsel | D056728;D014842 | T047 |
36,226,569 | ecl sensor combin paper electrod determin phenylalanin herein uniqu electrochemiluminesc ecl sensor combin paper electrod propos detect phenylalanin l phe blood sampl l phe detect perform convert l phe ammonia use phenylalanin ammonia lyas pal enzym ecl signal ru bpi produc combin ammonia co reactant report use aunp decor paper electrod obtain ecl signal ru bpi presenc nh produc ammonia molecul carri work electrod contact sampl cut sinc contact sampl matrix electrod develop method achiev excel select accord experiment data linear increas ecl signal logarithm vari l phe concentr mm observ correl coeffici r limit detect lod mm propos method effici appli l phe detect refer blood sampl averag recoveri calcul furthermor hplc uv method comparison verifi recoveri valu provid propos method accept similar l phe detect refer blood sampl result show develop ecl sensor combin paper electrod consid promis uniqu power techniqu point care diagnosi pku | D055664;D015374 | T059;T075 |
36,226,565 | prepar curcumin load cochleat characteris stabil antioxid properti curcumin cur wide rang applic function food howev disadvantag poor water solubl stabil solv problem cur encapsul cochleat encapsul effici diamet nm studi found stabil cur load cochleat cur coch improv compar curcumin load liposom cur lipo addit show dpph scaveng abil cur coch equival free cur addit cur coch could signific reduc mda content ldh releas increas sod activ h induc niht cell oxid damag model express nrf nqo protein obvious increas cur coch group indic cur coch could effect reduc niht cell damag caus h cur coch could improv stabil cur desir anti oxid abil may mean feasibl appli function food | D003474;D053758 | T121;T109;T073;T130 |
36,226,563 | role tnfsf variant oral cancer develop clinicopatholog characterist tumour necrosi famili superfamili tnfsf member tnfsf encod tnfsf regul immun respons inflamm howev role tnfsf singl nucleotid variant snvs former snps oral caviti squamous cell carcinoma ocscc remain unclear case control studi includ particip patient ocscc healthi control effect tnfsf rs rs rs cancer develop prognosi analys real time pcr genotyp assay genotyp tissu express gtex cancer genom atlas tcga databas use valid find result demonstr patient alter tnfsf snvs poorer histolog differenti wild type allel tnfsf snvs signific associ moder poor histolog differenti univari logist regress gtex databas express alter tnfsf snvs whole blood lower wild type allel howev express alter snvs upper aerodigest mucosa higher wild type allel tcga databas patient higher tnfsf express shorter overal surviv lower tnfsf express especi human papillomavirus negat advanc stage group conclus although tnfsf snvs affect ocscc develop patient alter tnfsf snvs exhibit poorer histolog differenti patient higher tnfsf express poorer prognosi lower tnfsf express | D020022;D009062 | T191;T032 |
36,226,560 | inhibit pseudomona aeruginosa lps induc airway inflamm ripk human airway although physiolog function receptor interact protein kinas ripk emerg critic mediat program necrosisnecroptosi intracellular role play attenu human lung human bronchial epithelia remain unclear show express ripk dramat decreas inflam tissu human lung move nucleus cytoplasm overexpress ripk dramat increas f actin format decreas express gene pro inflammatori cytokin il il sirna ripk interest wherea ripk bound histon b without lps stimul interact disrupt min lps treatment histon methyl could maintain bind ripk activ movement toward cytoplasm cytoplasm overexpress ripk continu attenu pro inflammatori cytokin gene express inhibit nf b activ prevent progress inflamm pseudomona aeruginosa infect data indic ripk critic regul lps induc inflammatori microenviron therefor suggest ripk potenti therapeut candid bacteri infect induc pulmonari inflamm | D008070;D011550 | T007;T109 |
36,226,552 | increas frequenc affirm name pronoun document pediatr emerg depart previous studi transgend gender divers youth region report made feel uncomfort emerg depart ed gender ident object studi conduct year qualiti improv project increas affirm name pronoun document pediatr ed | D005783;D004636 | T093;T041;T073;T032 |
36,226,546 | enantio diastereoselect approach indoloquinolizidin continu flow merg polym support asymmetr organocatalysi continu flow pack bed reactor use key enantiodetermin step short synthesi indoloquinolizidin use approach high enantioselect solvent free rapid conjug addit dimethyl malon divers famili cinnamaldehyd continu flow allow prepar relev oxodiest multigram amount develop obtain michael adduct use complet expedi diastereoselect synthesi indoloquinolizidin via cascad pictet splengler cyclis lactamis continu flow convers enantiopur michael adduct lacton via telescop reductioncyclis continu flow also explor | D007783 | T109 |
36,226,545 | peripher level monocyt myeloid deriv suppress cell first induct predict relaps surviv aml patient myeloid deriv suppress cell mdsc capabl suppress innat adapt immun respons thus favour solid cancer progress howev littl known role mdsc acut myeloid leukaemia aml monocentr prospect studi adult aml patient elig first line intens chemotherapi includ aim studi influenc long term outcom peripher blood pb level monocyt mdsc mdsc assess flow cytometri percentag peripher mdsc higher leukocyt diagnosi decreas mdsc induct came independ negat prognost factor leukaemia free overal surviv | D009364;D015470 | T191 |
36,226,540 | secondari donor deriv cd car therapi safe efficaci acut lymphoblast leukemia extramedullari relaps first autolog car therapi despit advanc treatment adult relapsedrefractori rr b lineag acut lymphoblast leukemia b poor prognosi expect five year overal surviv os rate nguyen et al oriol et al extramedullari relaps b regard high risk factor general associ poor surviv occur relaps patient ding et al sun et al central nervous system cns test common site extramedullari relaps b addit extramedullari leukemia appear skin eye breast bone muscl abdomin organ prognosi relaps extramedullari b allogen hematopoiet stem cell transplant allo hsct extrem poor spyridonidi et al dahlberg et al convent chemotherapi radiat often ineffect patient present optim treatment strategi treat extramedullari leukemia allo hsct | D018380;D054198;D000076962 | T116;T192;T061;T191;T129 |
36,226,539 | upf increas amino acid level promot cell prolifer lung adenocarcinoma via eif atf axi frameshift upf critic factor nonsens mediat messeng rna mrna decay nmd regul tumor associ molecular pathway mani cancer howev role upf lung adenocarcinoma luad amino acid metabol remain larg unknown studi found upf signific correl portion amino acid metabol pathway luad integr bioinformat metabolom confirm upf knockdown inhibit activ transcript factor atf ser phosphoryl eukaryot translat initi factor eif core protein amino acid metabol reprogram addit upf promot cell prolifer increas amino acid level luad cell depend function atf clinic upf mrna express abnorm luad tissu higher express upf atf signific correl poor overal surviv os luad patient find reveal upf potenti regul tumor associ amino acid metabol may therapeut target luad | D000077192;D008175 | T191 |
36,226,538 | iron metabol ferroptosi lncrna cancer known unknown cancer cell undergo substanti metabol alter sustain increas energi suppli uncontrol prolifer essenti trace element iron vital mani biolog process evid reveal cancer cell deploy various mechan elev cellular iron concentr acceler prolifer ferroptosi form cell death caus iron catalyz excess peroxid polyunsatur fatti acid pufa promis therapeut target therapi resist cancer previous studi report long noncod rna lncrna group critic regul involv modul cell metabol prolifer apoptosi ferroptosi review summar associ among iron metabol ferroptosi ferroptosi relat lncrna tumorigenesi inform help deepen understand role lncrna iron metabol rais possibl target lncrna ferroptosi cancer combin therapi | D000079403;D009369;D062085;D014131 | T191;T121;T123;T196;T114;T043 |
36,226,537 | tumor immun checkpoint associ inhibitor immunolog evas one defin characterist cancer immun modif immun checkpoint ic confer immun evas capabl tumor cell multipl ic program cell death protein pd cytotox lymphocyt associ antigen ctla bind respect receptor reduc tumor immun varieti way includ block immun cell activ signal ic blockad icb therapi target checkpoint molecul demonstr signific clinic benefit antibodi base ic inhibitor varieti specif small molecul inhibitor inhibit key oncogen signal pathway induc durabl tumor remiss patient varieti cancer deciph role regulatori mechan ic molecul provid crucial theoret guidanc clinic treatment review summar current knowledg function regulatori mechan ic molecul multipl level includ epigenet regul transcript regul post translat modif addit provid summari medic target various node regulatori pathway highlight potenti newli identifi ic molecul focus potenti implic cancer diagnost immunotherapi | D009369;D061026 | T191;T192;T116;T129 |
36,226,536 | tertiari lymphoid structur uniqu construct associ organ educ function tumor infiltr immunocyt tertiari lymphoid structur tlss format site persist inflammatori stimul includ tumor ectop lymphoid organ main consist chemo attract b cell cell support dendrit cell dcs matur tlss exhibit function organ optim develop collabor adapt immun respons deliv augment effect tumor microenviron tme descript posit correl tlss tumor prognosi reliabl certain condit involv local matur tlss emerg evid suggest under mechan anti tumor effect tlss pave way novel immunotherapi sever approach develop take advantag intratumor tlss either combin therapeut agent induc neogenesi tlss | D009369;D000072717 | T191;T024 |
36,226,535 | relaps car cell therapi b cell malign challeng futur approach chimer antigen receptor car cell therapi novel cellular immunotherapi dramat reshap landscap cancer treatment especi hematolog malign howev relaps still one troublesom obstacl achiev broad clinic applic intrins factor superior adapt tumor cell mark fundament aspect relaps uniqu biolog function car cell govern special car construct also affect treatment efficaci moreov complex cross interact among car cell tumor cell tumor microenviron tme profound influenc clinic outcom concern car cell function persist therefor review base recent discoveri focus challeng relaps car cell therapi b cell malign perspect tumor cell car cell tme also discuss correspond basic clinic approach may overcom problem futur aim provid comprehens understand scientist physician help improv research clinic practic | D009369;D000076962 | T191;T192;T116;T129 |
36,226,534 | cancer immunotherapi evolv paradigm inhibit host natur immun respons tumor cell wide report earli phase develop oncolog therapi concept employ host immun system treat cancer ie tumor immunotherapi new howev result earli theoret constraint clinic applic immunotherapi go smooth lag signific behind radiat chemotherapi path wind futur seem promis immunotherapi research advanc enorm result matur immuno edit theori creation numer technolog despit number unsuccess endeavor clinic studi sinc around us food drug administr fda approv varieti tumor immunotherapi includ cytokin interleukin interferon cancer vaccin proveng immun checkpoint inhibitor ipilimumab cellular therapi chimer antigen receptor car signal boom field | D019496;D009369;D000076962 | T116;T192;T121;T191;T129 |
36,226,533 | medic certif util shut protect health relat social need children famili face energi insecur greater odd poor health development problem studi famili request receiv medic certif util shut protect contact medic legal partnership mlp aim assess concurr health relat social need relat util hous financ nutrit | D000086382 | T047;T067 |
36,226,530 | glyphos ampa glyphos base herbicid exposur lead gfap pcna caspas increas immunoreact area male offspr rat hypothalamus glyphos aminomethylphosphon acid ampa glyphos base herbicid alter neuroendocrin axi content brain neurotransmitt behavior experiment anim model glyphos alon ampa roundup activ administ postpartum femal rat p p water consumpt measur daili immunoreact glial fibrillari acid protein gfap prolifer cell nuclear antigen pcna caspas measur anterior medial preoptic periventricular supraopt lateroanterior hypothalam nuclei p p male pup exposur via lactat xenobiot puppi expos glyphos moder level gfap overlap astrocyt process overlap observ roundup activ ampa exposur expos roundup activ ampa pcna posit cell strong immunoreact found hypothalam nuclei cell contain caspas found hypothalam nuclei studi label stronger roundup activ ampa exposur xenobiot signific increas immunoreact area marker studi major case p ampa roundup activ treat anim greater area pcna immunoreact control glyphos alon treat anim p effect observ xenobiot exposur due increas water intak increas immunoreact area observ marker studi suggest xenobiot induc neuro inflammatori respons impli increas cell prolifer glial activ induct apoptot pathway find also show glyphos metabolitesadjuv andor surfact present glyphos commerci formul greater effect glyphos alon summari glyphos ampa glyphos base herbicid alter gfap caspas pcna express rat hypothalamus alter neuroendocrin axi | D006540 | T131 |
36,226,526 | facil prepar novel chitosan deriv porous graphit carbon biomateri high effici captur n glycan comprehens character n glycan signific import discoveri potenti biomark diagnosi therapi diseas herein design fabric porous graphit carbon biomateri cs c use cheap avail chitosan carbon sourc via facil pyrolysi process post oxid strategi effect captur n glycan thank larg surfac area g high graphit degre suitabl oxid degre uniqu porous structur cs c biomateri exhibit ultralow detect limit ng l excel size exclus effect ova digest bsa protein ova protein www satisfactori reusabl least cycl captur standard n glycan moreov cs c success appli profil differ n glycan diabet progress obes impair glucos toler diabet patient healthi control discov express level five n glycan show gradual increas trend diabet progress remark five specif n glycan could consid biomark accur diagnos progress diabet work develop novel porous graphit carbon biomateri larg scale character n glycan also provid new guidanc precis therapi diabet | D002244;D048271 | T121;T109;T196 |
36,226,523 | non aqueous bond leuprorelin ochratoxin peptid base solid phase extract anticanc therapeut leuprorelin found excel affin carcinogen ochratoxin ota equilibrium constant k dissoci constant k nm function mesopor polym bind surfac bound leuprorelin mycotoxin corrobor dft calcul extend extract ota heavili fatti matric coffe achiev recoveri improv cyclabl compar immunoaffin work present potenti peptid mycotoxin interact durabl non aqueous extract | D009793;D009183 | T109;T131 |
36,226,516 | regio diastereoselect transit metal free hydroalkyl n allenyl sulfonamid push pull alkynylquinolin describ novel effici synthet strategi construct linear homoallyl quinolon structur intermolecular addit alkynylquinolin n allenyl sulfonamid develop regio diastereoselect transit metal free hydroalkyl dien structur contain push pull system moreov present work carri high atom economi mild reaction condit moder high yield | D013449;D028561 | T121;T109;T196 |
36,226,512 | high accuraci determin trace element total reflect x ray fluoresc spectrometri use freez dri specimen total reflect x ray fluoresc txrf analysi conduct determin trace element sampl solut drop onto substrat dri therefor form residu affect quantit result absorpt x ray fluoresc xrf follow lambert beer law absorpt effect xrf thick residu dot type residu stronger thin residu film type residu absorpt effect particular remark determin low z element high element concentr solut studi propos new film like residu prepar process base freez dri method obtain accur txrf result sampl solut drop onto substrat insert chamber chamber cool use liquid nitrogen result aliquot sampl frozen chamber depressur use vacuum pump freez dri residu prepar maintain chamber room temperatur evalu effici freez dri base method sampl prepar txrf analysi prepar multi element solut contain high element concentr compon residu prepar use freez dri method relat standard deviat quantit valu minimum detect limit improv absorpt effect weaken sampl prepar process base freez dri method facilit accur txrf analysi high element concentr solut appli analysi trace element differ type solut environment water wastewat | D014131 | T121;T123;T196 |
36,226,509 | abnorm neural stem cell lesch nyhan diseas lesch nyhan diseas lnd neurodevelopment disord caus variant hprt gene encod enzym hypoxanthin guanin phosphoribosyl transferas hgprt hgprt defici provok numer metabol chang vari among differ cell type make unclear chang relev abnorm neural develop begin elucid consequ hgprt defici develop human neuron neural stem cell nscs prepar induc pluripot stem cell ipsc line individu lnd compar normal healthi control line gene express profil determin rna seq protein express profil determin shotgun proteom lnd line reveal signific chang express multipl gene protein littl overlap find ipsc nscs confirm impact hgprt defici depend cell type nscs gene express studi point toward abnorm wnt signal known play role neural develop protein express studi point abnorm mitochondri f f atpas play role maintain cellular energi studi point mechan may respons abnorm neural develop lnd | D007926;D058953 | T047;T025 |
36,226,508 | novel tripl mutant extremophil glycosyl hydrolas enabl rapid synthesi thioglycosid order expand toolbox enzym avail thioglycosid synthesi describ first exampl extremophil glycosyl hydrolas halothermothrix orenii hor gh engin toward thioglycosynthas activ novel combin mutat use tripl mutant hor gh mreaeg rang thioglycosid glycosyl fluorid donor aromat thiol could synthesis exquisit stereoselect good excel convers | D013865;D000071825 | T001;T109 |
36,226,506 | enabl perfus multicellular tumor spheroid promot lumen vascular cancer model tumor compos heterogen cell popul known tumor stroma particular blood vessel indispens role tumor microenviron act key player anti cancer drug deliveri recent effort made accur recapitul microenviron employ distinct cell type howev proper format perfus tumor tissu challeng perfus tumor tissu engin implant multicellular tumor spheroid insid microfluid devic blood perfus spheroid growth vascular dynam monitor accord spheroid composit contribut intern extern vascular cell spheroid perfus analyz notabl increas penetr depth fluoresc conjug anti cancer drug observ tri cultur spheroid implement tumor microenviron reconstruct develop studi creat perfus tumor vascular model also util novel drug screen platform patient deriv sampl | D009369;D000970 | T191;T109;T121 |
36,226,505 | iodin ammonium persulf mediat activ dmso approach n formyl amid synthesi isatin effici strategi toward n formyl amid oxid indolin isatin describ method employ readili avail nh dmso given method featur oper simplic excel function group toler broad substrat scope fast kinet moreov method appli synthesi natur product alatamid notabl dmso play three vital role formyl group sourc oxid solvent | D007455;D007510 | T121;T109;T123;T196;T130 |
36,226,504 | cell administr rout heart failur compar evalu regener dcm regener ihd trial aim given logist issu surround intramyocardi cell deliveri sought address efficaci simpler access intracoronari rout evalu regener dcm regener ihd autolog cell therapi trial heart failur n method retrospect statist analysi perform trial combin data follow end point evalu left ventricular eject fraction lvef n termin pro brain natriuret peptid concentr nt probnp new york heart associ class nyha qualiti life result demonstr new efficaci signal intracoronari deliveri signific benefit lvef p nt probnp median pgml p nyha class patient p qualiti life p improv lvef nyha qualiti life score remain signific compar control group conclus efficaci logist simplic intracoronari deliveri taken consider futur trial | D016277;D006333 | T046;T047;T042 |
36,226,500 | mof coat upconvers nanoconstruct synerget photo chemodynamicoxygen elev photodynam therapi excess product intracellular reactiv oxygen speci ros induc apoptosi cancer cell howev often limit sever trigger condit hypox microenviron solid tumor address issu herein design mof coat upconvers nanoconstruct uctscf refer uc cetf msio mil cufe synerget photochemodynam therapi pct oxygen elev photodynam therapi pdt mof mil fe coat cu dope design catalyz h overexpress cancer cell generat cytotox oh via chemodynam therapi cdt note uc repres nm driven upconvers nanoparticl high tissu penetr depthlow heat effect design provid intens blue light reliev sever trigger condit cdt via pct furthermor function layer photosensit chlorin e ce carri triethoxi h h h h nonafluorohexyl silan tfs co dope mesopor silicon cetf msio caus oxygen elev product upon nm light irradi simpl ros generat nanoplatform heighten antitumor effect via oxygen elev synerget tumor pctpdt | D010778;D011166;D053758 | T061;T109;T123;T073 |
36,226,488 | dietari fiber obtain caulerpa lentillifera prevent high fat diet induc obes mice regul gut microbiota metabolit profil due expand farm grow consumpt caulerpa lentillifera receiv extens attent present studi physicochem properti insolubl dietari fiber c lentillifera cl idf evalu vitro rrna sequenc analysi well non target metabolom perform investig hypolipidem effect cl idf combin supplement cl tdfs compos cl idf solubl polysaccharid c lentillifera vivo result show cl idf exhibit superior physicochem capac bind water oil glucos addit cl idf cl tdf administr could regul gut microbiota increas acet propion acid level restor metabol disord amino fatti bile acid obes mice notabl consid process cost c lentillifera equal anti obes effect cl idf cl tdfs fresh whole food supplement c lentillifera may cost effect way prevent obes | D046068;D000069196 | T007;T001;T002 |
36,226,463 | inflammatori serum factor aortic valv stenosi patient modul sex differ valvular myofibroblast activ osteoblast like differenti aortic valv stenosi av sexual dimorph cardiovascular diseas driven fibrosi calcif aortic valv leaflet circul inflammatori factor present serum av patient contribut sex differ valv fibro calcif drive activ valvular interstiti cell vic myofibroblast andor osteoblast like cell howev molecular mechan inflammatori factor contribut sex specif valv fibro calcif remain larg unknown studi identifi inflammatori factor present serum sampl av patient regul sex specif myofibroblast activ osteoblast like differenti correl serum proteom dataset clinic vitro myofibroblast dataset identifi annexin cystatin c candid inflammatori factor correl av patient sever myofibroblast activ measur vitro valid experi util hydrogel biomateri cell cultur platform mimic valv extracellular matrix confirm annexin cystatin c promot sex specif vic activ myofibroblast via p mapk signal addit annexin cystatin c increas osteoblast like differenti primarili male vic result implic serum inflammatori factor potenti av biomark also contribut sexual dimorph av progress drive vic myofibroblast activ andor osteoblast like differenti collect result herein overal understand biolog sex may impact inflamm driven av may lead develop sex specif drug treatment strategi | D001024;D017306;D002114 | T047;T046;T123;T116 |
36,226,462 | dual function nanoplatform base nir green dual emiss persist luminesc nanoparticl x ray excit persist luminesc imag photodynam therapi persist luminesc nanoparticl plnps possess advantag high sensit bioimag continu photodynam therapi pdt emit persist luminesc perl excit ceas howev plnps limit singl wavelength emiss effici realiz one function bioimag pdt addit plnps excit shallow tissu penetr excit light make difficult achiev repeat vivo applic high effici herein x ray excit plnps zn ga ge cr mn zggcm dual emiss vivo x ray repeat activ perl imag tumor pdt report first time zggcm exhibit dual emiss peak x ray excitationr excit locat nm nm respect addit zggcm modifi photosensit rose bengal rb construct dual function nanoplatform base perl imag pdt result indic perl emiss peak nm cr ion zggcm possess excel near infrar nir perl imag perform green perl emiss peak nm mn ion activ rb effect generat reactiv oxygen speci ros therebi caus signific antitumor effect uniqu dual function nanoplatform expect promot applic plnps integr effici tumor diagnosi treatment | D010778;D053758;D009369 | T191;T061;T073 |
36,226,457 | account basic self employ physician work self employ physician liber activ practic requir masteri medic art also financi manag practic articl aim remind basic account notion necessari adequ financi manag medic practic | D000066;D005376;D010820;D011216 | T058;T057;T081;T097 |
36,226,456 | complic cerebr ventricular shunt intern ventricular shunt system drain excess cerebrospin fluid anoth bodi caviti patient hydrocephalus subject complic sometim difficult identifi lead diagnost error practition enough awar frequent complic mechan drainag dysfunct infecti interrupt drainag may causeneurolog sign intracrani hypertens diagnosi usual easi howev clinic sign sometim less obvious dysfunct shunt evok multidisciplinari manag neurosurgeri team necessari evalu appropri investig emerg manag | D002557;D006849 | T061;T047;T019;T033 |
36,226,455 | infecti diseas never read second part covid epidem turn live upsid surpris certain aspect infect also make smile well certain mode transmiss infecti agent group togeth form origin blooper infecti diseas | D000086382;D003141 | T047;T067 |
36,226,454 | number need treat use toolto evalu effect treatment articl review clinic implic limit number need treat nnt clinician quick use rather intuit statist valu assess expect effect treatment explain patient howev care attent must paid outcom use defin nnt well rate specif event popul durat observ conflict interest may also affect easili manipul statist tool often prescrib treatment nnt well impli uncertain benefit patient emphas need care weigh risk benefit balanc nnt vs nnh number need harm prescrib review show particular low nnts anti infecti agent compar drug frequent use medic practic | D018570 | T058;T080;T062 |
36,226,453 | central nervous system infect target therapi consid develop target therapi revolution approach immunosuppress sever medic specialti prescrib therapi familiar agent general internist infecti diseas specialist must deal consequ product enceph prompt appropri manag paramount challeng patient undergo immunomodulatori therapi atyp present involv particular germ potenti brain toxic immunomodulatori treatment articl outlin mechan action target therapi review associ brain infect | D002494 | T047 |
36,226,452 | hantavirus infect hantavirus envelop zoonot rna virus host rodent respons america hantavirus pulmonari syndrom europ caus hemorrhag fever renal syndrom milder form nephropathia epidemica diseas begin abrupt high fever chill headach back pain abdomin pain associ nausea vomit diagnosi primarili made serolog current specif medic prevent avail europ treatment symptomat | D006476;D018778;D006480 | T047;T005 |
36,226,451 | clostridioid difficil infect various therapeut approach european american infecti diseas societi publish new guidelin treatment clostridiod difficil coliti opt chang practic fidaxomicin recommend first line treatment vancomycin second choic metronidazol remain recommend case treatment avail choic endors swiss infecti diseas societi still propos metronidazol first line treatment matter fact inexpens treatment still present satisfactori efficaci strain clostridoid difficil found switzerland context patient without risk factor low probabl relaps | D016360;D003015 | T007;T047;T037 |
36,226,450 | methicillin suscept staphylococcus aureus bacteraemia methicillin suscept staphylococcus aureus bacteremia frequent constant increas switzerland associ high morbiditymort despit antibiot treatment two clinic case discuss epidemiolog pathophysiolog clinic present treatment diseas histori clinic examin remain central order guarante optim manag | D016470;D055624;D013203 | T007;T047 |
36,226,446 | electrochemiluminesc dual turn strategi alkalin phosphatas detect use dual quench ru bpi encapsul zeolit imidazol metal organ framework electrochemiluminesc dual turn strategi first design detect alkalin phosphatas alp use dual quench ru bpi encapsul zeolit imidazol metal organ framework ru bpi zif reson energi transfer ecret make ecl turn ascorb acid phosphat hydrolyz po ascorb acid aa alp po decompos ru bpi zif aa prevent ecret make ecl turn | D000073396;D017641;D015374 | T059;T075;T109;T197 |
36,226,434 | surgic treatment infecti ulnar arteri aneurysm infecti ulnar arteri aneurysm rare condit standardis treatment patient treat simpl proxim ligatur without excis aneurysm | D000783;D003141 | T047;T046;T190 |
36,226,433 | coercion ambul set patient resist medic assist undo safeti strap ambul stretcher ambul personnel known make use blanket bandag velcro strap restrain patient transit studi aim establish often type coercion use | D000552;D004632 | T093;T073;T061;T058;T074 |
36,226,432 | systemat screen substanc use upon hospitalis mani peopl improv health reduc consumpt alcohol habit form medic screen connect emerg hospit admiss help reduc use | D006760;D019966 | T058;T048;T033 |
36,226,431 | supplementari drug treatment reduc weight adolesc sever obes norwegian medicin agenc approv use daili inject liraglutid mg saxenda supplement lifestyl treatment weight control children year age obes isobmi share treatment experi six multidisciplinari obes clinic specialist health servic | D019440;D009767 | T121;T047 |
36,226,425 | monitor follow acut stroke improv mani serious complic follow acut stroke prevent treat requir close systemat monitor follow stroke | D002545;D020521 | T047;T046 |
36,226,410 | select corf g quadruplex bind small molecul amelior patholog signatur alsftd model g quadruplex g form corf ggggcc gc expand hexanucleotid repeat ehr predomin genet caus amyotroph later sclerosi al frontotempor dementia ftd develop select g bind ligand challeng due conform polymorph similar g structur identifi three first class marin natur product chrexanthomycin ca chrexanthomycin b cb chrexanthomycin c cc remark bioactiv thereinto ca show highest permeabl lowest cytotox live cell nmr titrat experi silico analysi demonstr ca cb cc select bind dna rna gc gs notabl ca cc dramat reduc gc ehr caus cell death diminish gc rna foci gc express neuroa cell signific elimin ros ht cell gc express drosophila ca cc signific rescu eye degener improv locomotor deficit overal find reveal ca cc potenti therapeut agent deserv clinic studi | D000690;D001688;D057180 | T121;T047;T123;T048 |
36,226,399 | treatment hyperthyroid clinician access panel therapeut option treat hyperthyroid drug nuclear medicin surgeri use take care patient quit often differ option propos patient choic made base individu case presenc comorbid urgenc situat famili context patient wish paper review main therapeut option discuss key point allow choos appropri treatment | D006980;D013965 | T061;T047 |
36,226,398 | apalutamid erleada androgen depriv therapi adt either bilater orchiectomi treatment gonadotropin releas hormon analogu agonist antagonist mainstay treatment advanc prostat cancer metastat set although adt initi effect castrat resist diseas eventu develop almost men prostat cancer sinc addit docetaxel abirateron enzalutamid apalutamid darolutamid docetaxel adt shown improv overal surviv os patient start adt metastat diseas castrat resist occur diseas progress despit testosteron castrat rang common rare without detect metastas addit next generat antiandrogen adt shown improv os patient high risk nonmetastat castrat resist prostat cancer nmcrpc identifi psa doubl time dt month apalutamid nonsteroid antiandrogen agent bind direct ligand bind domain androgen receptor without agonist activ ad adt apalutamid shown improv os patient start adt metastat prostat cancer patient upfront metastat diseas previous treatment curat intent similar apalutamid shown provid month os improv patient nmcrpc short psa dt os benefit obtain cost term qualiti life apalutamid given oral day well toler common side effect fatigu rash hypertens hot flush potenti interact concomit medic taken account | D057466;D064129 | T191;T109 |
36,226,397 | manag nippl areolar complex anomali nippl areolar complex anomali may secondari mani etiolog simpl anatom variat malign process paget diseas invas breast cancer pass benign local aggress process eros adenomatosi nippl differenti diagnosi alway simpl clinic exam standard radiolog checkup ca nt confirm benign lesion biopsi specimen obtain allow anatomopatholog examin precis diagnosi made lead optim manag paper describ explor nippl areolar complex anomali uncommon clinic case associ independ invas retro areolar cancer dermatolog diseas areola mimick paget diseas | D000236;D001943;D010212 | T191 |
36,226,396 | heart failur preserv eject fraction hfpef heart failur preserv left ventricular eject fraction hfpef serious condit constant increas preval correl increas diseas risk factor incid obes arteri hypertens diabet etc age popul first challeng diagnosi hfpef two score base algorithm propos european esc hfa peff score american accaha hfpef score cardiolog societi help clinician differenti diagnosi exert dyspnea score includ associ various sign elev ventricular fill pressur rest andor exercis accord esc recommend manag hfpef current base symptomat treatment diuret treatment co morbid treatment under etiolog identifi end diagnost approach prognosi diseas pejor treatment demonstr effect hfpef phenotyp control studi manag algorithm could chang soon due public emperor preserv studi demonstr efficaci empagliflozin sglt inhibitor concern signific reduct mortal rate cardiac hospit regardless left ventricular eject fraction said mani ongo studi field treatment prospect like target hfpef phenotyp near futur due heterogen natur clinic entiti | D006333;D000077203 | T121;T047;T046;T109 |
36,226,395 | evolut histocompat method organ transplant updat evalu anti hla immun organ transplant evolv dramat sinc first lymphocytotox crossmatch donor recipi describ true hla type perform high resolut sequenc nevertheless transplant total compat organ remain except appear anti hla antibodi transplant inevit condit long term surviv graft new comput tool current develop evalu quantifi degre incompat donor recipi view predict risk reject adapt immunosuppress therapi target manner patient | D006680;D016377 | T061;T116;T129 |
36,226,394 | tricuspid regurgit transcathet treatment triclip tricuspid regurgit tr rare associ poor clinic outcom sever etiolog tr function case usual associ left side valvular heart diseas sever tr respons right heart failur may evolv global heart failur current echocardiograph classif includ sever grade trivial moder sever massiv torrenti tr influenc patient prognosi increment manner manag patient sever tr discuss heart team evalu surgic risk tri score may use evalu intra hospit mortal risk case isol tricuspid surgeri isol tr surgeri rare perform surgic risk outweigh expect clinic benefit transcathet treatment sever tr may consid high select case transcathet edg edg repair teer restor leaflet coaptat first tricuspid teer procedur perform mitraclip abbott santa clara ca usa devic specif devic develop triclip abbott prospect multicent trilumin trial evalu triclip procedur patient symptomat moder sever tr high surgic risk result show good efficaci reduct post procedur tr grade increas nyha function class minut walk test distanc right ventricular function qualiti life year devic current evalu develop ie transcathet tricuspid implant non surgic tr manag like evolv improv signific soon | D006333;D019918;D014262 | T061;T047;T046 |
36,226,393 | impact prolong second stage labor perinat morbid experi manag second stage labor optim durat controversi particular nullipar women aim analyz impact prolong second stage perinat morbid institut | D007748;D007744 | T046;T079 |
36,226,392 | alcohol atrial fibril atrial fibril af common heart rhythm disord increas preval current estim world popul long well known holiday heart syndrom acut alcohol consumpt bing drink may trigger episod af often benign immedi consumpt meta analys observ studi clear shown signific associ high level alcohol consumpt risk af accord studi includ meta analys conclus may differ regard associ low moder level alcohol consumpt risk af associ probabl exist level consumpt least one drink per day heavi alcohol consumpt appear increas risk complic patient af light moder alcohol consumpt causal natur relationship alcohol consumpt af current confirm deni given contradictori result mendelian random studi publish date howev patient diagnos af recommend abstain alcohol result strong reduct consumpt made possibl signific reduc recurr af episod | D001281 | T047;T046 |
36,226,391 | wearabl cardiovert defibril sudden cardiac death affect close half million peopl year europ account cardiovascular death unfortun minor event occur front wit reduc chanc surviv order limit risk intern automat defibril implant patient risk sudden cardiac death howev circumst patient risk sudden cardiac death devic implant order limit risk certain patient equip wearabl defibril | D017147;D000076251 | T074;T073 |
36,226,390 | rare complic dog bite capnocytophaga speci bacteremia follow hemolyt urem syndrom dog bite frequent reason medic consult respons sever infecti complic bacteria genus capnocytophaga speci gram negat bacilli common found oral caviti certain anim dog cat follow dog bite wound contamin anim spit bacteria caus local cellul system invas manifest bacteremia endocard mening lead rare dread complic thrombot microangiopathi identif capnocytophaga slow due specif characterist cultur condit treatment capnocytophaga speci infect base antibiot therapi amoxicillin clavulan acid first choic although differ type capnocytophaga describ c canimorsus appear associ higher rate atyp complic descript immunocompet patient present c canimorsus bacteremia complic hemolyt urem syndrom follow dog bite | D016470;D001733;D002371;D004283;D016905;D006463 | T047;T037 |
36,226,389 | mucin nevus mucin nevus except entiti present flesh color brownish papul plaqu coalesc form pigmentari verruc lesion either blaschkoid linear group zosteriform disposit usual appear birth earli childhood late onset also describ mucin nevus requir addit work intern patholog describ abstent therapeut intervent usual prefer | D009506;D012868;D012878 | T191;T019 |
36,226,379 | narrat review calcitonin peptid famili associ receptor migrain target calcitonin gene relat peptid beyond summar pharmacolog calcitonin peptid famili receptor explor relationship migrain current migrain therapi | D015740;D008881 | T047;T116;T125 |
36,226,362 | differ chromat nois suppress lumin contrast discrimin young elder peopl age caus impair contrast sensit chromat discrimin lead chang perceptu interact color lumin inform aim investig influenc chromat nois lumin contrast threshold young older adult forti particip divid equal young year old elder group year old perform lumin contrast discrimin task presenc chromat nois masker use mosaic stimulus mosaic background four chromat nois mask protocol appli protan deutan tritan nois protocol found lumin contrast threshold signific elev addit chromat nois age group p elder group younger group threshold obtain tritan protocol lower obtain protan deutan protocol p protocol lumin contrast threshold elder particip higher young peopl p tritan chromat nois less effect inhibit lumin discrimin elder particip | D003118;D015350 | T041 |
36,226,357 | rapid sar cov nucleocapsid protein profil assay high sensit compar nucleic acid detect exist nucleic acid antigen profil method covid diagnosi fail simultan meet demand sensit detect speed hamper comprehens way epidem prevent control thus effect screen covid requir simpl fast sensit method report rapid assay ultrasensit high specif profil covid associ antigen assay base bind induc dna assembl nanoparticl scaffold act fluoresc translat bind two aptam target protein protein bring dna region close proxim form close loop conform result format fluoresc translat use assay saliva nucleocapsid protein n protein profil quantit convert n protein molecul inform fluoresc signal fluoresc intens enhanc increas n protein concentr caus metal enhanc fluoresc use simpl specif fast profil assay within min basi assay enabl high recognit ratio limit detect fg ml order magnitud lower exist commerci antigen elisa kit compar superior pcr base nucleic acid test owe rapid ultrasensit well easi oper hold great promis tool screen covid epidem monkey pox | D000086382;D009696 | T047;T123;T067;T114 |
36,226,356 | assess relationship matern risk attent deficit hyperact disord function connect biolog toddler attent deficit hyperact disord adhd neurodevelopment disord associ increas risk poor educ attain compromis social integr current clinic diagnosi rare occur school age despit behavior sign adhd earli childhood known brain biomark adhd risk children age year old | D001289 | T048 |
36,226,354 | hepatoprotect effect nanoniosom load myristica fragran phenol compound mice induc hepatotox studi nanoniosom load myristica fragran mf phenol compound nlmp synthes character physic properti hepatoprotect effect mice liver toxic induc l asparaginas la inject accord result nlmp spheric shape nm diamet zeta potenti mv polydispers index pdi weight feed intak mice induc hepatotox signific p increas treat nlmp mgkg bodi weight mice addit blood level triglycerid tg cholesterol chol liver enzym aspart aminotransferas ast alanin transaminas alt alkalin phosphatas alp total bilirubin signific p decreas signific increas p blood level antioxid defenc system glutathion peroxidas gpx superoxid dismutas sod catalas cat also report nlmp treatment nlmp also led signific decreas p inflammatori relat gene express induc nitric oxid synthas ino interferon gamma ifn liver well meaning p increas express sod antioxid status biomark consequ nlmp recommend potenti dietari supplement allevi symptom la induc hepatotox | D026323;D056486 | T047;T168;T002;T037 |
36,226,353 | thioether analogu pituitari neuropeptid oxytocin via thiol ene macrocyclis unprotect peptid disulfid bond essenti featur mani bioactiv peptid howev labil reduc condit limit therapeut applic herein report effici methodolog peptid macrocyclis furnish thioether mimet disulfid linkag via thiol ene click chemistri furthermor methodolog appli effici synthesi analogu neuropeptid oxytocin high effici rout clinic therapeut carbetocin | D013438;D009479 | T109;T123;T116 |
36,226,351 | nod mediat hdacnf b signal pathway regul ferroptosi induc extracellular histon h acut liver failur acut liver failur alf life threaten often associ high mortal rate aim present studi investig whether extracellular histon h could induc ferroptosi hepat macrophag alf explor potenti mechan raw macrophag cbl mice use studi lps galactosamin gal histon h histon h antibodi nod agonist muramyl dipeptid mdp hdac sirna administ studi key molecul ferroptosi nod hdac nf b pathway detect vitro histon h releas extracellular environ cell nucleus lps exposur addit histon h could induc ferroptosi raw macrophag increas level fe ros decreas level gpx gsh mdp aggrav ferroptosi raw macrophag stimul histon h accompani elev nod hdac p p ib hdac sirna amelior ferroptosi raw macrophag induc histon h accompani decreas level hdac p p ib howev hdac sirna alter nod level raw macrophag administ histon h vivo level nod hdac nf b pathway ferroptosi increas alf mice downregul histon h antibodi upregul histon h extracellular histon h could induc ferroptosi hepat macrophag alf regul thenod mediat hdacnf b signal pathway | D000079403;D017114 | T043;T047 |
36,226,336 | search rescu incid among person year older usa examin factor associ death older peopl vulner becom lost home especi alon unfamiliar environ incid older person becom lost frequent report often requir search rescu sar respons becom lost distress person concern carer famili may result physic injuri andor death studi examin factor associ death among older person report lost home | D017028;D018635 | T098;T097;T099;T057 |
36,226,332 | surviv caus death among peopl clinic diagnos dementia lewi bodi multicent cohort studi comprehens studi surviv caus death peopl clinic diagnos dementia lewi bodi dlb aim studi investig surviv caus death dlb | D000544;D014150;D020961;D011014 | T050;T047;T121;T048;T039 |
36,226,323 | efficaci safeti sotrovimab patient covid rapid review meta analysi therapeut potenti sotrovimab treatment coronavirus diseas covid controversi issu aim studi evalu efficaci safeti sotrovimab covid patient end pubm cochran librari embas web scienc medrxiv googl scholar search august refer list key studi also scan find addit record meta analysi perform use comprehens meta analysi seventeen studi involv patient includ signific differ observ mortal rate odd ratio ci p hospitalis rate ci p hospit death rate ci p need mechan ventil ci p icu admiss ci p sotrovimab receiv group compar sotrovimab howev signific differ observ two group term diseas progress ci p emerg depart visit ci p two group signific differ term incid advers event ci p find present meta analysi support sotrovimab could effect safe treatment option reduc mortal hospitalis rate delta omicron variant covid | D000086382 | T047;T067 |
36,226,312 | integr singl cell rna sequenc analysi identifi key immun cell dendrit cell associ gene particip myocard myocard complex diseas character myocardi inflammatori cell infiltr purpos studi investig gene singl cell signatur explor involv immun cell myocard gene express merg gse gse dataset subject differenti express gene deg analysi ppi network construct correl analysi deg immun cell infiltr perform singl cell rna sequenc scrna seq download gse total deg identifi includ deg upregul deg downregul myocard group compar control group go kegg enrich analys reveal myocard trigger deg main involv immun relat process pathway ppi network analysi identifi central hub gene occurr myocard induc signific enrich convent dendrit cell cdc plasmacytoid dc plasma cell myocardi tissu mmp gpnmb atpvd express posit correl cdc abund mmp gpnmb share hub gene list total cell scrna seq yield cell cluster annot cell type includ fibroblast neutrophil stromal cell monocyt basophil b cell natur killer cell innat lymphoid cell cell proport natur killer cell monocyt higher myocard control monocyt annot subclust includ dc macrophag monocyt hub gene ctss mpeg cybb h ab ly cd lgal high express monocyt cluster among dc correl deg mmp main express monocyt cluster gpnmb main express fibroblast cluster wherea atpvd express weaker signal weaker cell prefer conclus dc infiltr associ pivot gene may respons progress myocard studi expand provid novel inform immun cell engag myocard | D020869;D009205 | T059;T047;T063 |
36,226,270 | effect chronic heart failur longitudin chang cognit function elder patient elder patient cognit impair present problem memori loss impair judgment loss languag function sever case affect daili life social function past year possibl diseas possibl ill chronic heart failur chf elder patient continu increas howev enough research effect chf longitudin chang speed cognit function elder patient studi focus effect diseas like hypertens coronari heart diseas diabet cognit function elder patient result incomplet research context articl use bayesian network build cognit function classif model elder effect chf rate longitudin chang cognit function elder patient studi mental state examin statist method experi final conclud evalu attent languag abil memori abil elder patient elder chf incid cognit impair experiment result indic higher degre chf elder patient lower level cognit function articl could help advanc research prevent delay cognit declin patient chf | D003072;D006333 | T047;T046;T048 |
36,226,269 | predict chang tumor regress radiotherapi nasopharyng carcinoma use comput tomographi base radiom work aim explor applic valu comput tomographi ct base radiom predict chang tumor regress radiotherapi nasopharyng carcinoma work patient nasopharyng carcinoma underw concurr chemoradiotherapi ccrt hospit januari decemb select patient divid radiosensit group case insensit group case accord tumor volum shrinkag radiotherapi slicer softwar use delin tumor region interest roi total radiom featur extract use radiom modul softwar group within group consist test one way anova lasso dimension reduct three omic featur final select establish predict model time age gender tumor stage n stage hemoglobin albumin patient collect establish clinic predict model result show compar logist regress decis tree random forest adaboost model svm model base ct radiom featur best perform predict tumor regress chang tumor radiotherapi train group area receiv oper characterist curv auc confid interv ci valid group auc ci compar support vector machin svm predict model base clinic featur svm model base radiom featur better perform predict chang retract tumor radiotherapi train group omic featur svm model auc clinic featur svm model valid group omic featur svm model auc clinic featur svm model p base radiom characterist clinic characterist patient nomo predict map establish calibr curv show good consist visual assist clinic judgment work predict model compos ct base radiom featur combin clinic featur accur predict withdraw chang tumor radiotherapi ensur accuraci treatment plan minim number ct scan radiotherapi | D015233;D009303 | T191;T170;T081 |
36,226,268 | meta analysi long term efficaci prolif diabet retinopathi base intellig medic treatment order solv problem subhealth high chronic diseas diagnosi treatment valu ad diabet retinopathi studi particular diabet high chronic diseas pose great threat peopl health continu improv nation health awar medic field also begin pay attent diagnosi treatment valu ad diabet retinopathi order improv long term treatment valu ad diabet retinopathi intellig medic monitor systemat scientif efficaci analysi evalu purpos studi explor effect achiev meta analysi long term efficaci prolif diabet retinopathi intellig medic treatment studi diabet retinopathi system help doctor achiev unlimit sign paramet acquisit transmiss build matur treatment result monitor platform time conclus base vitrectomi propos effect improv surgic efficaci patient prolif diabet retinopathi | D003920;D003930 | T047 |
36,226,247 | diagnosi earli gastric cancer base medic imag technolog mathemat model key reduc mortal gastric cancer earli detect earli diagnosi earli treatment gastric cancer earli diagnosi gastric cancer key earli detect diagnosi gastric cancer earli diagnosi treatment gastric cancer great signific improv curat effect reduc mortal gastric cancer purpos paper studi diagnosi earli gastric cancer base medic imag techniqu mathemat model effect w deeplab network assist diagnosi imag white light analyz valu narrow band imag blue laser imag diagnosi earli gastric cancer compar blue laser imag endoscopi clear observ demarc line microvascular morpholog use narrow band imag observ part demarc line microvascular morpholog observ result show blue laser imag brighter narrow band imag endoscop imag easier observ microstructur lesion endoscopi accur determin natur lesion | D013274 | T191 |
36,226,246 | analysi data fludarabin cyclophosphamid rituximab chemoimmunotherapi chronic lymphocyt leukemia show high patient heterogen need consider individu treatment data singl cell rna sequenc rna seq cll patient obtain gene express omnibus databas r packag util analyz data relat result predict via genemania websit inform sampl cover three stage observ stage pretreat cit rituximab fludarabin cyclophosphamid pre cit post cit differenti express gene deg identifi function enrich analys perform b cell subpopul pseudotim trajectori analysi conduct | D015451 | T191 |
36,226,245 | analysi diabet diseas risk predict diabet medic pattern base data mine diabet mellitus second common diseas cardiovascular diseas malign tumor continu acceler peopl live standard life rhythm number diabet patient rapid increas show trend youth recent studi found million adult china diabet high preval rate awar rate treatment rate complianc rate low diabet treat control time various complic occur cardiovascular cerebrovascular diabet foot great impact surviv patient also caus lot pressur famili societi therefor prevent control diabet import strategi save medic resourc reduc medic cost paper main read lot literatur accumul import theoret knowledg clarifi basic principl method data mine refer research result scholar select new combin algorithm model combin k mean algorithm logist regress algorithm construct predict model diabet explor law medic diabet patient base analysi | D002318;D003924;D017719 | T047 |
36,226,244 | combin methotrex leflunomid effici safe patient rheumatoid arthriti present work aim explor clinic efficaci safeti methotrex mtx leflunomid lef combin therapi rheumatoid arthriti june june total individu rheumatoid arthriti receiv diagnosi sixti patient random assign control observ group observ group receiv mtx lef combo medic control group receiv mtx treatment clinic efficaci complic incid allevi inflammatori marker joint pain clinic symptom compar group posttreat observ group overal respons rate control group signific differ compar pretreat control observ group patient show decreas trend il level increas trend il level posttreat signific differ p compar control group patient observ group lower il tnf level signific differ p higher level il signific differ p group pain score number pain joint much lower prior treatment follow treatment observ group display signific lower level erythrocyt sediment rate rheumatoid factor c reactiv protein control group p clinic measur observ group lower control group statist signific differ p conclus combin therapi mtx lef efficaci rheumat arthriti | D001172;D008727 | T121;T047;T109 |
36,226,243 | establish valid machin learn predict model base big data predict risk bone metastasi renal cell carcinoma patient sinc prognosi renal cell carcinoma rcc patient bone metastasi bm poor studi aim use big data build machin learn ml model predict risk bm rcc patient | D001859;D002292;D007680;D009362 | T191 |
36,226,242 | predict conserv water molecul bind site protein use machin learn method combin featur water molecul play import role mani biolog process term stabil protein structur assist protein fold improv bind affin well known due impact various environment factor difficult identifi conserv water molecul cwms free water molecul fwms direct cwms normal deepli embed protein form strong hydrogen bond surround polar group circumv difficulti work abund spatial structur inform physicochem properti water molecul protein inspir us adopt machin learn method identifi cwms therefor studi machin learn framework identifi cwms bind site protein present first analyz water molecul physicochem properti spatial structur inform six featur ie atom densiti hydrophil hydrophob solvent access surfac area temperatur b factor mobil extract featur analyz combin reach higher cwm identif rate result optim featur combin determin base optim combin seven differ machin learn model includ support vector machin svm k nearest neighbor knn decis tree dt logist regress lr discrimin analysi da nave bay nb ensembl learn el evalu abil identifi two categori water molecul ie cwms fwms show el model desir predict model due comprehens advantag furthermor present methodolog valid case studi crystal skh extens compar dowser predict perform show optim featur combin desir el model method could achiev satisfactori predict accuraci identifi cwms fwms protein bind site | D000069550;D014867 | T121;T066;T197 |
36,226,241 | outcom nurs base health belief unit knowledg belief practic mode gastroscopi patient gastric cancer gastric cancer detect earli screen scientif reason intervent method select time condit effect control routin nurs unabl obtain satisfactori result effect improv complianc examin outstand research aim estim outcom nurs base health belief combin knowledg belief practic gastroscopi patient gastric cancer | D005773;D013274 | T191;T061;T060 |
36,226,240 | unsupervis imag registr network brain mri deform registr recent year deep learn made success applic remark achiev field medic imag registr method medic imag registr base deep learn becom current research hotspot howev perform convolut neural network may fulli exploit due neglect spatial relationship distant locat imag incomplet updat network paramet avoid phenomenon mhnet multiscal hierarch deform registr network brain mr imag propos paper network unsupervis end end convolut neural network train dens displac vector field predict almost real time unseen input imag pair save lot time compar tradit algorithm independ iter optim pair imag basi encod decod structur network introduc improv incept modul multiscal featur extract expand recept field hierarch forecast structur promot updat paramet middl layer achiev best perform augment public dataset compar exist four excel registr method | D021621;D008279 | T073;T059;T060;T170;T062 |
36,226,239 | mine potenti biomark pathway valvular atrial fibril vaf via systemat screen gene coexpress network appli bioinformat method excav potenti gene therapeut target associ valvular atrial fibril vaf | D001281;D035683 | T047;T046;T123;T114 |
36,226,238 | comparison clinic pregnanc outcom fresh frozen embryo transfer analyz clinic outcom patient underw fresh frozen embryo transfer well neonat outcom | D002585;D011256 | T061;T079;T033 |
36,226,237 | yap overexpress breast cancer cell promot angiogenesi activ yap signal vascular endotheli cell yap signal pathway alter implic oncogen human mammari cancer howev role yap signal regul breast tumor angiogenesi remain elus tumor angiogenesi coordin activ cancer cell vascular endotheli cell whether yap signal pathway regul intercellular interact cancer cell endotheli cell essenti unknown | D042702;D001943 | T121;T116;T191 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.